Diabetes
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Diabetes Home
    • Products
      Diabetes Treatments
    • Professional Resources
      Product Resources Library Insulin & Type 1 Diabetes
  • Sample Requests
    • Diabetes Education
      Clinical Education Library Diabetes Risk Assessment Tool
    • Treatment Guidelines
      ADA Standards of Care AACE Diabetes Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Library
    • Prescription Savings & Coverage
      Savings Cards Insurance Coverage Affordability Resources ICD-10 Codes for Diabetes
    • Support Program
      Diabetes Management
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg logo
Important Safety Information | Patient Site
Prescribing Information
    • Ozempic® Overview
    • Mechanism of Action
    • FAQs
    • Ozempic® and A1C
    • Ozempic® and Weight
    • Special Populations
    • Safety Profile
  • T2D and Cardiovascular Disease (CVD)
  • T2D and Chronic Kidney Disease (CKD)
    • Dosing and Prescribing
    • Ozempic® Pen
    • Disease State Information
    • Cost and Coverage
    • HCP Resources
    • Patient Resources
    • For Pharmacists
    • Samples
Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg logo

Prescribing Information
Important Safety Information | Patient Site

Ozempic® (semaglutide) injection is the only GLP-1 RA indicated for adults with T2D and CKD1

to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death1

CV=cardiovascular; T2D=type 2 diabetes; CKD=chronic kidney disease; SOC=standard of care

Two women walking and holding water bottles

Actor portrayals

Ozempic® (semaglutide) injection is the only GLP-1 RA indicated for adults with T2D and CKD1

to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death1

CV=cardiovascular; T2D=type 2 diabetes; CKD=chronic kidney disease; SOC=standard of care

Women walking with water bottles

For many patients, T2D is just the beginning3,4,5

 Early diagnosis and slowing the progression of CKD in patients with T2D is key

Blue kidneys icon
Blue anatomical heart icon

40%

of patients with T2D
have CKD6,7,b

  • Patients with T2D and CKD are at higher risk of major ASVD events including death3,8
  • Even early-stages of CKD increase the risk for CV morbidity and mortality in patients with T2D3,6
  • CKD is an important risk factor for CVD—As eGFR declines and uACR increases, the risk of CV morbidity escalates3,6

aReported in the 2022 ADA/KDIGO consensus report6,7

ASCVD=atherosclerotic cardiovascular disease; CKD=chronic kidney disease; CV=cardiovascular disease; T2D=type 2 diabetes; uACR=urine albumin-creatinine ratio.

Help protect your patients by reducing their risk of CKD progression1,2

For adults with T2D, for the primary composite endpoint: Time to first occurrence of ≥50% sustained eGFR decline, kidney failure (sustained eGFR <15 mL/min/1.73m2, or initiation of long-term dialysis, or transplantation), or renal or CV death vs placebo when added to standard of care1,2,a

Cumulative incidence: Time to first occurrence of the primary composite endpoint1-3,b,c

Ozempic®  CKD progression statistic
Time to first occurrence of the CKD composite primary endpoint graph

aThe eGFR was calculated with serum creatinine level and the Chronic Kidney Disease Epidemiology Collaboration 2009 formula. Events not related to the eGFR were evaluated by the event adjudication committee. Sustained was defined as having 2 consecutive measurements ≥28 days apart by fulfilling the criteria.2
b
A cumulative incidence function (CIF) plot graphically shows the probability of an event occurring over time, from randomization to the first event in the presence of competing risks. The relative risk reduction is calculated based on the sum of the events in the trial.4
c
Cumulative incidence estimates are based on time from randomization to first composite renal event with non-CV and non-renal death modeled as competing risk. The x-axis in truncated at 52 months where approximately 5% of the population was in the trial. Median follow-up was 41 months1,2
d
Cox proportional hazards model with treatment as factor and stratified by baseline use of SGLT2-inhibitor at baseline (yes or no)
eTwo-side P value for the test of no difference. The Significance level was 0.03224.1
f
4.9% ARR reported at 3 years in a prespecified supplementary analysis.3

ARR=absolute risk reduction; CI=confidence interval; CV=cardiovascular; CVD=cardiovascular disease; eGFR=estimated glomerular filtration rate; GLP-1 RA=glucagon-like peptide-1 receptor agonist; RRR=relative risk reduction; SGLT2=sodium-glucose cotransporter 2; T2D=type 2 diabetes.

FLOW evaluated renal and cardiovascular outcomes with Ozempic® once weekly in adults with T2D and CKD

Ozempic® in FLOW: the only GLP-1 RA indicated for T2D and CKD.1,2

A randomized, double-blind, placebo-controlled, event-driven trial that followed 3533 patients with type 2 diabetes and chronic kidney disease (eGFR 25 to 75 mL/min/1.73 m2 with UACR > 100 mg/g and <5000 mg/g) for a median follow-up of 41 months.1,2

At baseline, patients had a mean eGFR of 47 mL/min/1.73 m2  and a median UACR of 568 mg/g (11% of patients had an eGFR <30 mL/min/1.73 m2 and 69% of patients with UACR >300 mg/g at baseline).1,2

At baseline, 95% of patients were treated with an ACE inhibitor or ARB, 16% were on an SGLT-2i, 76% were on a statin, and 50% were on an antiplatelet agent.1,2

FLOW: kidney outcomes study design

FLOW evaluated renal function with Ozempic once weekly

gRandomization was stratified according to SGLT-2 inhibitor use at baseline.2

hAn 8-week dose-escalation regimen was used, with dose escalation from 0.25 mg per week for 4 weeks then 0.5 mg per week for another 4 weeks, followed by maintenance dose of 1 mg per week throughout remainder of the treatment period.2

iDuring the trial, investigators were encouraged to optimize standard-of-care treatment for T2D, CKD, and CVD risk management according to local treatment practice.6

jSustained was defined as having 2 consecutive measurements ≥28 days apart fulfilling the criteria. Death from cardiovascular causes included both death from cardiovascular cause and death from undetermined causes.2

ACE=angiotensin-converting enzyme; ARB=angiotensin II receptor blocker; CI=confidence interval; CKD=chronic kidney disease; CV=cardiovascular; eGFR=estimated glomerular filtration rate; GLP-1 RA=glucagon-like peptide-1 receptor agonist; MACE=major adverse cardiovascular event; OAD=oral antidiabetic drug; RAAS=renin-angiotensin-aldosterone system; SGLT2=sodium glucose co-transporter; T2D=type 2 diabetes; UACR=urine albumin-creatinine ratio.

68% of patients were at very high risk for CKD progression2,k

Patient characteristics at baseline (N=3533)1,2

kPatients were classified as very high risk for CKD progressing according to Kidney Disease: Improving Global Outcomes (KDIGO) risk calculators based on GFR and albuminuria categories.2

lFor eGFR, the baseline assessment is defined as the mean of the two assessments from the randomization visit and the screening visit. If only one of the assessment was available, it was used as the baseline assessment. The mean eGFR is based on the serum creatinine level and the Chronic Kidney Disease Epidemiology Collaboration 2009 equation.2

mThe urinary albumin-to-creatinine ratio was calculated  with albumin measured in milligrams and creatinine measured in grams.2

BMI=body mass index; CKD=chronic kidney disease; eGFR=estimated glomerular filtration rate; UACR=urine albumin-creatinine ratio.

Majority of patients were treated with standard of care1,2,n,o

Summary of medication at baseline (N=3533)1,2

Select CV and CKD baseline characteristics (N=3533)1,2

Summary of CV medication usage at baseline chart

nAt baseline patients in FLOW were receiving standard-of-care background therapy, including a maximum tolerated label dose of a RAAS-blocking agent including an ACE inhibitor or an ARB, unless such treatment was contraindicated or not tolerated.1

oInvestigators were encouraged to optimize standard-of-care treatment for T2D, CKD, and CV risk management according to local treatment practice.6

ACE=angiotensin-converting enzyme; ARB=angiotensin II receptor blocker; CKD=chronic kidney disease; CV=cardiovascular; eGFR=estimated glomerular filtration rate; RAAS=renin-angiotensin-aldosterone system; SLT-2i=sodium glucose co-transporter-2 inhibitor; UACR=urine albumin-creatinine ratio.

Ozempic® achieved significance in the primary composite endpoint1,2

For adults with T2D and CKD, for the primary composite endpoint: Time to first occurrence of ≥50% sustained eGFR decline, kidney failure (sustained eGFR <15 mL/min/1.73 m2, or initiation of long-term dialysis, or transplantation), or renal or CV death vs placebo when both were added to standard of care1,2,p

Ozempic®  CKD progression statistic
Composite primary endpoint graph

This study was not powered to detect a difference in the individual endpoints of the composite primary endpoint. 

Overall, the primary composite endpoint occurred in 331 patients of 1767 (18.7%) on Ozempic® (1 mg) and 410 patients of 1766 (23.2%) on placebo (HR, 0.76 [95% Cl; 0.66-0.88] P=0.0001 for superiority). 1

≥50% sustained eGFR decline occurred in 165 patients (9.3%) on Ozempic® and 213 patients (12.1 %) on placebo. Sustained eGFR <15 mL/min/1.73 m2 occurred in 92 patients (5.2%) on Ozempic® and 110 patients (6.2%} on placebo. Chronic renal replacement therapy occurred in 87 patients (4.9%) on Ozempic® and 100 patients (5.7%) on placebo. Renal death occurred in 5 patients (0.3%} on Ozempic® and 5 patients (0.3%) on placebo. Cardiovascular death occurred in 123 patients (7.0%) on Ozempic® and 169 patients (9.6%) on placebo.1

pSustained was defined as having 2 consecutive measurements ≥28 days apart fulfilling the criteria.1
q
A cumulative incidence function (CIF) plot graphically shows the probability of an event occurring over time. From randomization to the first event in the presence of competing risks. The relative risk reduction is calculated based on the sum of events in the trial.4
r
4.9% ARR reported at 3 years in prespecified supplementary analysis3
s
Data are for the full analysis population from the in-trial period (from randomization to the end of trial participation). Data from participants without events of interest were censored at the end of their in-trial period. Median follow-up was 41 months1,2
t
Cox proportional hazards model with treatment as factor and stratified by baseline use of SGLT2-inhibitor at baseline (yes or no).1
u
Two-sided p value for the test of no difference. The significance level was 0.03224.1
v
Death from cardiovascular causes, as confirmed by the event adjudication committee, includes both death from cardiovascular causes and death from undetermined causes adjudicated by that committee.2

ARR=absolute risk reduction; CI=confidence interval; CKD=chronic kidney disease; CV=cardiovascular; eGFR=estimated glomerular filtration rate; GLP-1 RA=glucagon-like peptide-1 receptor agonist; RRR=relative risk reduction; SOC=standard of care; SLT-2i=sodium glucose co-transporter inhibitor; T2D=type 2 diabetes.

CKD confirmatory secondary endpoints

Significant 18% RRR of MACE with Ozempic®2

For adults with T2D and CKD, for a confirmatory secondary endpoint: Time to first occurrence of MACE (CV death, nonfatal MI, or nonfatal stroke) vs placebo when both were added to standard of care1,2

Time to first major adverse cardiovascular event (MACE)1-3,w-z

Kidney Outcomes MACE

wCumulative incidence estimates are based on time from randomization to first EAC-confirmed MACE with non-CV death modelled as a competing risk using the Aalen-Johnson estimator. The x-axis is truncated at 52 months where approximately 5% of the population was in the trial.1

xComposite major cardiovascular events were analyzed in a time-to-first-event analysis with a Cox proportional-hazards model with treatment as a categorical fixed factor and stratified according to SGLT-2 inhibitor use as baseline.2

yData from participants without events of interest were censored at the end of their in-trial period.2

zDeath from cardiovascular causes, as confirmed by the even adjudication committee, includes both death from cardiovascular cause and from undetermined causes adjudicated by that committee.

aaTwo-sided p-value for the test of no difference. The significance level was 0.03224.1

bb2.2% ARR reported at 3 years in a prespecified supplementary analysis.3

ARR=absolute risk reduction; CI=confidence interval; CKD=chronic kidney disease; CV=cardiovascular; EAC=external adjudication committee; eGFR=estimated glomerular filtration rate; GLP-1 RA=glucagon-like peptide-1 receptor agonist; MACE=major adverse cardiovascular event; MI=myocardial infarction; RRR=relative risk reduction; SOC=standard of care; SLT-2i=sodium glucose co-transporter inhibitor; T2D=type 2 diabetes.

Significant reduction in all-cause mortality with Ozempic®1

For adults with T2D and CKD for a confirmatory secondary endpoint: time to first occurrence of all-cause mortality vs placebo when both were added to standard of care1,2

Ozempic®  mortality statistic

All cause death1,2,3

cc2.5%ARR reported at 3 years in pre-specified supplementary analysis.3

ddCox proportional hazards model with treatment as factor and stratified by baseline use of SGLT2-inhibitor at baseline (yes or no).1

eeTwo-sided p value for the test of no difference. The significance level was 0.03444.1

Ozempic® reduced the annual rate of change in eGFR1

For adults with T2D and CKD for a confirmatory secondary endpoint: observed mean change in eGFR over time (the annual rate of change in eGFR) vs placebo when both were added to standard of care1,2

Observed mean plot: eGFR(mL/min/1.73m2) by week in FLOW trial1,2,ff

ffObserved data from the in-trial period until week 104. Error bars are +/- 1.96 *standard error of the mean eGFR, which was calculated using the CKD-EPI 2009 formula.1

For CKD benefit

Recommended Dosage for Patients with Type 2 Diabetes and Chronic Kidney Disease:

Initiate Ozempic® with a dosage of 0.25 mg once weekly for 4 weeks. After 4 weeks on the 0.25 mg, increase the dosage to 0.5 mg once weekly. Increase to the maintenance dosage, 1 mg once weekly, after at least 4 weeks on the 0.5 mg dosage.

View dosing information

For patients with T2D and CVD and/or CKD

Clinical guidelines support a comprehensive approach to T2D management10

The 2022 American Diabetes Association and European Association for the Study of Diabetes consensus report identified 4 key cornerstones that current T2D treatment should address: hyperglycemia, weight, CV risk factor management, and cardiorenal protection10

Guidelines recommend starting CKD screening at diagnosis of T2D,
since evidence of CKD is often already apparent at this time.6

Kidney Disease Improving Global Outcomes

CV=cardiovascular; CVD=cardiovascular disease; CKD=chronic kidney disease; T2D=type 2 diabetes

WHAT A CARDIOLOGIST IS SAYING ABOUT OZEMPIC®

"As a cardiologist, you either prescribe or recommend to your colleagues a medication with proven CVD benefit and label indication for patients with T2D and established CVD. So you have to know about Ozempic®."

DR JOSHUA STOLKER | CARDIOLOGIST

Learn about Ozempic®

More ways to help your patients with T2D

Open hand and dollar sign icon

NovoCare® provides treatment affordability options

See cost and coverage »

 

 


Bar chart icon

See if Ozempic® is an option for your patients

Learn about Ozempic® »

Important Safety Information for Ozempic® (semaglutide) injection

WARNING: RISK OF THYROID C-CELL TUMORS

  • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Ozempic® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined
  • Ozempic® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Ozempic® and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Ozempic®

Indications and Usage

Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is indicated:

  • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
  • to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes and established CV disease
  • to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease

Important Safety Information cont.

Contraindications

  • Ozempic® is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a hypersensitivity reaction to semaglutide or to any of the excipients in Ozempic®. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with Ozempic®

Warnings and Precautions

  • Risk of Thyroid C-Cell Tumors: Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging
  • Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide. Observe patients carefully for signs and symptoms of pancreatitis (persistent severe abdominal pain, sometimes radiating to the back with or without vomiting). If pancreatitis is suspected, discontinue Ozempic® and initiate appropriate management
  • Diabetic Retinopathy Complications: In a 2-year trial involving patients with type 2 diabetes and high cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with Ozempic® (3.0%) compared with placebo (1.8%). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline than among patients without a known history of diabetic retinopathy.
    Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. The effect of long-term glycemic control with semaglutide on diabetic retinopathy complications has not been studied. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy
  • Never Share an Ozempic® Pen Between Patients: Ozempic® pens must never be shared between patients, even if the needle is changed. Pen-sharing poses a risk for transmission of blood-borne pathogens
  • Hypoglycemia: Patients receiving Ozempic® in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia
  • Acute Kidney Injury Due to Volume Depletion: There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with semaglutide. The majority of reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea. Monitor renal function in patients reporting adverse reactions to Ozempic® that could lead to volume depletion, especially during dosage initiation and escalation
  • Severe Gastrointestinal Adverse Reactions: Use of Ozempic® has been associated with gastrointestinal adverse reactions, sometimes severe. In Ozempic® clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients receiving Ozempic® (0.5 mg 0.4%, 1 mg 0.8%) than placebo (0%). Ozempic® is not recommended in patients with severe gastroparesis
  • Hypersensitivity: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with Ozempic®. If hypersensitivity reactions occur, discontinue use of Ozempic®; treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist
  • Acute Gallbladder Disease: Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing. In placebo-controlled trials, cholelithiasis was reported in 1.5% and 0.4% of patients treated with Ozempic® 0.5 mg and 1 mg, respectively, and not reported in placebo-treated patients. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated
  • Pulmonary Aspiration During General Anesthesia or Deep Sedation: Ozempic® delays gastric emptying. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking Ozempic®

Adverse Reactions

  • The most common adverse reactions, reported in ≥5% of patients treated with Ozempic® are nausea, vomiting, diarrhea, abdominal pain, and constipation

Drug Interactions

  • When initiating Ozempic®, consider reducing the dose of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia
  • Ozempic® causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications, so caution should be exercised

Use in Specific Populations

  • There are limited data with semaglutide use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. Discontinue Ozempic® in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide

Please click here for Ozempic® Prescribing Information, including Boxed Warning.

References:

  1. Ozempic® [package insert]. Plainsboro, NJ: Novo Nordisk Inc.
  2. Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391:109-121.
  3. Data on file. Novo Nordisk Inc; Plainsboro, NJ.
  4. Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133(6):601-609.
  5. Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. Supplementary appendix. N Engl J Med. 2024;391:109-121.
  6. Rossing P, Baeres FMM, Bakris G, et al. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023;38(9):2041-2051.
Diabetes
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
  • Diabetes Home
  • Product Information
    Products
    • Diabetes Treatments
    Professional Resources
    • Product Resources Library
      Insulin & Type 1 Diabetes
  • Sample Requests
  • Professional Education
    Diabetes Education
    • Clinical Education Library
      Diabetes Risk Assessment Tool
    Treatment Guidelines
    • ADA Standards of Care
      AACE Diabetes Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Library
    Prescription Savings & Coverage
    • Savings Cards
      Insurance Coverage
      Affordability Resources
      ICD-10 Codes for Diabetes
    Support Program
    • Diabetes Management

Ozempic® is a registered trademark and novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.

Terms of Use | Privacy Notice | Consumer Health Privacy Notice | Cookie Notice | Privacy Request | Contact Us |
novonordisk-us.com    
© 2025 Novo Nordisk All rights reserved. US24OZM00390 February 2025

Quick links

Request medication samples

Diabetes treatment guidelines

Patient savings card offer

Patient support program